China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal
Chinese biopharmaceutical firm Innovent Biologics and U.S. pharma giant Pfizer have struck a global licensing and collaboration deal worth up to $10.5 billion to research and develop 12 early-stage cancer medicines, the companies said on Friday.
(Reporting by Sherin Sunny in Bengaluru; editing by Alan Barona)
Copyright Reuters or USA Today Network via Reuters Connect
This story was originally published May 28, 2026 at 7:19 PM.